Income statement and cash flow are strong; balance sheet is moderate.
Next earnings: 2026-11-04 (AMC), EPS Forecast: $2.67
Upgraded from Sell to Buy in the Jun 2025 quarter: 56.2 → 66.1 (+9.9). This quarter: +3.0.
Change vs previous quarter.
steris is a leading provider of infection prevention and procedural surgical products and services, focused primarily on healthcare, pharmaceutical, research and medical device customers. our mission is to provide a healthier today and a safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. while the corporation was founded as innovative medical technologies in 1985 and renamed steris in 1987, our history dates back to 1894 with the founding of american sterilizer company, a long-time, global leading innovator of sterilization products. today, through a series of strategic acquisitions and continual innovation of new products, steris holds one of the broadest portfolios of products in the industry. it stands at the forefront of efforts to prevent infection and contamination in healthcare, pharmaceutical and medical device environments.